NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04549207 2025-11-28
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT04067726 2025-10-16
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04586660 2025-10-01
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Amgen
Phase 4 Active not recruiting
NCT04711109 2025-04-02
BRCA-P
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03324932 2023-10-06
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Kyoto Prefectural University of Medicine
Phase 3 Active not recruiting